Masato Takahashi
About
Masato Takahashi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Masato Takahashi has authored 294 papers receiving a total of 17.0k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Oncology, 99 papers in Pulmonary and Respiratory Medicine and 79 papers in Surgery. Recurrent topics in Masato Takahashi's work include HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (46 papers) and Kawasaki Disease and Coronary Complications (44 papers). Masato Takahashi is often cited by papers focused on HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (46 papers) and Kawasaki Disease and Coronary Complications (44 papers). Masato Takahashi collaborates with scholars based in Japan, United States and Germany. Masato Takahashi's co-authors include Jane W. Newburger, Jane C. Burns, Stanford T. Shulman, Michael H. Gewitz, Kathryn A. Taubert, Michael A. Gerber, Patricia Ferrieri, Anne H. Rowley, Brian W. McCrindle and Lloyd Y. Tani and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.
In The Last Decade
Masato Takahashi
279 papers receiving 16.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Masato Takahashi Japan | 48 | 9.5k | 8.7k | 3.5k | 2.8k | 2.7k | 294 | 17.0k | ||
| Gerald J. Berry United States | 73 | 6.7k 0.7× | 5.3k 0.6× | 3.1k 0.9× | 2.8k 1.0× | 2.8k 1.0× | 336 | 19.6k | ||
| Shaf Keshavjee Canada | 85 | 17.1k 1.8× | 11.0k 1.3× | 1.4k 0.4× | 2.5k 0.9× | 3.5k 1.3× | 870 | 29.3k | ||
| Henry D. Tazelaar United States | 71 | 5.1k 0.5× | 7.7k 0.9× | 4.0k 1.2× | 2.5k 0.9× | 1.7k 0.6× | 335 | 16.8k | ||
| Douglas B. Cines United States | 75 | 5.6k 0.6× | 2.9k 0.3× | 1.7k 0.5× | 1.1k 0.4× | 3.3k 1.2× | 357 | 22.8k | ||
| Samuel A. Yousem United States | 64 | 6.9k 0.7× | 6.9k 0.8× | 739 0.2× | 3.0k 1.1× | 1.3k 0.5× | 284 | 14.4k | ||
| John A. Belperio United States | 64 | 3.7k 0.4× | 6.4k 0.7× | 765 0.2× | 3.6k 1.3× | 2.6k 1.0× | 255 | 15.2k | ||
| Scott M. Palmer United States | 64 | 7.0k 0.7× | 4.7k 0.5× | 777 0.2× | 1.4k 0.5× | 982 0.4× | 345 | 12.3k | ||
| Eric L. Matteson United States | 84 | 2.8k 0.3× | 10.3k 1.2× | 1.3k 0.4× | 1.2k 0.4× | 2.6k 1.0× | 465 | 25.5k | ||
| Marshall I. Hertz United States | 63 | 13.1k 1.4× | 4.8k 0.6× | 2.4k 0.7× | 1.7k 0.6× | 691 0.3× | 235 | 16.9k | ||
| Thomas W. Wakefield United States | 64 | 7.4k 0.8× | 3.1k 0.4× | 3.7k 1.1× | 654 0.2× | 1.6k 0.6× | 335 | 17.8k |
Countries citing papers authored by Masato Takahashi
Since
Specialization
Citations
This map shows the geographic impact of Masato Takahashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masato Takahashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masato Takahashi more than expected).
Fields of papers citing papers by Masato Takahashi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Masato Takahashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masato Takahashi. The network helps show where Masato Takahashi may publish in the future.
Co-authorship network of co-authors of Masato Takahashi
This figure shows the co-authorship network connecting the top 25 collaborators of Masato Takahashi. A scholar is included among the top collaborators of Masato Takahashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masato Takahashi. Masato Takahashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tolaney, Sara M., Valentina Guarneri, Jae Hong Seo, et al.. (2024). Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European Journal of Cancer. 199. 113555–113555.
2.
Fujii, Shintaro, Hiroaki Yaguchi, Takashi Inoue, et al.. (2024). Anti-Tr/DNER Antibody-associated Paraneoplastic Neurological Syndrome Presenting Limbic Encephalitis with Anaplastic Large Cell Lymphoma. Internal Medicine. 64(13). 2057–2061.
3.
Yamamoto, Kensuke, S. Ban, K. Ieki, et al.. (2023). Development of ultra-low mass and high-rate capable RPC based on Diamond-Like Carbon electrodes for MEG II experiment. Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment. 1054. 168450–168450.
4.
Takahashi, Masato, Tomofumi Osako, Hiroyuki Yasojima, et al.. (2023). Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole. Breast Cancer. 31(1). 53–62.
5.
Shiroiwa, Takeru, Kojiro Shimozuma, Hiroji Iwata, et al.. (2022). Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. Clinical Drug Investigation. 42(3). 253–262.
6.
Yamashiro, Hiroyasu, Hiroji Iwata, Norikazu Masuda, et al.. (2020). Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer. 27(4). 631–641.
7.
Yamashita, Toshinari, Norikazu Masuda, Shigehira Saji, et al.. (2020). Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 21(1). 391–391.
8.
Inoue, Kenichi, Masato Takahashi, Hirofumi Mukai, et al.. (2020). Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Investigational New Drugs. 38(5). 1540–1549.
9.
Yamaguchi, Takeshi, Yasuo Hozumi, Yasuaki Sagara, et al.. (2020). The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. Surgical Oncology. 36. 51–55.
10.
Takahashi, Masato, Shoichiro Ohtani, Shigenori E. Nagai, et al.. (2020). The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. Breast Cancer Research and Treatment. 185(1). 125–134.
11.
André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940.
12.
Yasuno, Fumihiko, Hiroaki Kazui, Katsufumi Kajimoto, et al.. (2017). 認知的に正常な高齢者における脳アミロイドβと末梢リンパ球の相互作用【Powered by NICT】. International Journal of Geriatric Psychiatry. 32(12). 93–99.
13.
Aihara, Tomohiko, Tatsuya Toyama, Masato Takahashi, et al.. (2016). The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. Breast Cancer. 23(3). 329–342.
14.
Yamashita, Hiroko, Akiko Ogiya, Tadahiko Shien, et al.. (2015). Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 23(6). 830–843.
15.
Mukai, Hirofumi, Tomohiko Aihara, Yutaka Yamamoto, et al.. (2014). The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. Breast Cancer. 22(1). 5–15.
16.
Kubo, Makoto, Noriko Kanaya, Jingjing Ye, et al.. (2012). Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Research and Treatment. 137(1). 93–107.
17.
Takahashi, Masato. (2009). BUILDING OWNERS' RESPONSIBILITY AND TENANTS' ONE IN STOCK ERA. Journal of Architecture and Planning (Transactions of AIJ). 74(645). 2459–2464.
18.
Miyoshi, Yasuo, Masafumi Kurosumi, Junichi Kurebayashi, et al.. (2009). Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer. 17(2). 103–109.
19.
Miyoshi, Yasuo, Masafumi Kurosumi, Junichi Kurebayashi, et al.. (2007). Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. Journal of Cancer Research and Clinical Oncology. 134(5). 561–567.
20.
Li, Jennifer S., Eric Yow, Katherine Berezny, et al.. (2007). Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease. Circulation. 116(3). 293–297.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gerald J. Berry Breakdown of academic impact, for papers by Shaf Keshavjee Breakdown of academic impact, for papers by Henry D. Tazelaar Breakdown of academic impact, for papers by Douglas B. Cines Breakdown of academic impact, for papers by Samuel A. Yousem Breakdown of academic impact, for papers by John A. Belperio Breakdown of academic impact, for papers by Scott M. Palmer Breakdown of academic impact, for papers by Eric L. Matteson Breakdown of academic impact, for papers by Marshall I. Hertz Breakdown of academic impact, for papers by Thomas W. Wakefield